

ELRON

Translation of Immediate Report Filed by Elron on March 12, 2018 with the Israeli Securities Authority

Tel Aviv, March 12, 2018 – Elron Electronic Industries Ltd. (TASE: ELRN) ("Elron") announced with respect to BrainsGate Ltd. ("BrainsGate") as follows:

Further to Item 4 of Elron's Form 20F for 2016 published on March 21, 2017 and Elron's Immediate Report filed on Form 6K on September 5, 2017, BrainsGate updated the Company that the last patient has been enrolled in its clinical trial thereby completing the clinical trial patient enrollment. Once the 90-day follow-up of the last patient is completed, the trial results will be collected, processed, and analyzed. Top-line results are expected to be announced in the third quarter of 2018.

BrainsGate's above estimates are forward-looking in nature, as defined in Israel Securities Law, 5728-1968, and are based on BrainsGate's estimations of the timing and progress of the follow-up period and trial analysis, and on information existing in BrainsGate as of the date of this immediate report. These estimates, in whole or in part, may not materialize, or may materialize in a manner materially different than expected. The principal factors that may cause material differences are developments in BrainsGate's field of operation, unforeseen trial results, patient follow-up issues, reliance on third parties including data analysis services, failure to meet goals, inability to realize technologies, modifications in technologies, modifications in the business plan, goals and/or strategy, or if any risk associated with the course of the trial and its results occurs.

BrainsGate is approximately 30% held by Elron.